Link Between NAFLD and Coronary Artery Disease: Metabolic Risks Beyond Genetics
Overview
Recent Mendelian randomization analysis found no causal genetic link between non-alcoholic fatty liver disease (NAFLD) and coronary artery calcification (CAC). Instead, metabolic dysfunction appears to mediate the association, highlighting NAFLD as a marker of advanced metabolic risk rather than a direct cause of coronary artery disease (CAD).
Background
NAFLD has been associated with increased risk of cardiovascular diseases including atherosclerosis, myocardial infarction, and stroke. The newer term metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes metabolic risk factors and broadens diagnostic criteria beyond NAFLD. The relationship between liver steatosis and coronary artery calcification (CAC) may depend on disease severity, particularly liver fibrosis. However, whether NAFLD causally contributes to CAC or shares common metabolic risk factors remains debated.
Data Highlights
The two-sample Mendelian randomization study by He et al. analyzed European genome-wide association data and found no significant causal genetic association between NAFLD and CAC. Reverse analyses and sensitivity validations confirmed these findings, suggesting metabolic factors rather than genetics drive the NAFLD-CAC link.
Key Findings
No causal genetic association was found between NAFLD and coronary artery calcification using Mendelian randomization.
Metabolic risk factors such as insulin resistance, obesity, and dyslipidemia likely mediate the relationship between NAFLD and CAC progression.
Advanced NAFLD stages with liver fibrosis are more strongly linked to pro-inflammatory cytokines and oxidative stress, increasing cardiovascular risk.
NAFLD should be viewed as a marker of systemic metabolic dysfunction requiring comprehensive cardiovascular risk assessment.
Social determinants of health, including socioeconomic factors, are important considerations in managing patients with metabolic liver disease and CAD.
Clinical Implications
Clinicians should interpret NAFLD as an indicator of advanced metabolic dysfunction rather than a direct genetic cause of coronary artery disease. Comprehensive evaluation and management of metabolic risk factors and lifestyle interventions are essential to reduce cardiovascular risk in these patients. Additionally, addressing social determinants of health is critical to optimize prevention strategies and improve outcomes.
Conclusion
The association between NAFLD and coronary artery disease is primarily driven by shared metabolic risk factors rather than direct genetic causation. A holistic, patient-centered approach targeting metabolic health and social factors is key to reducing cardiovascular morbidity in this population.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
